(HealthDay)—A considerable proportion of patients with lung cancer are prescribed medications that prolong the corrected QT (QTc) interval, limiting their eligibility for clinical trials, according to a study published ...
Dec 16, 2019
0
3
The Cancer Atlas, 3rd edition, a comprehensive global overview of cancer around the globe, concludes that progress in the fight against cancer is not only possible, but achievable. The report was produced by the American ...
Oct 16, 2019
0
2
Cyclooxygenase-2 is overexpressed in bladder cancer cells, making it an attractive molecular target for the detection and treatment of cancer.
Oct 15, 2019
0
5
Desperate for nutrients, rapidly growing pancreatic tumors resort to scavenging "fuel" through an alternative supply route, called macropinocytosis. Scientists are hopeful that blocking this process, often described as "cellular ...
Jun 27, 2019
0
0
A new pilot study demonstrated the feasibility of using molecular tumor markers as the basis for selecting the chemotherapeutic agents to use in patients with metastatic pancreatic cancer. Based on these promising results ...
Jun 10, 2019
0
1
Use of statins before or after a diagnosis of colorectal cancer was linked with a lower risk of premature death, both from cancer and from other causes, in a Cancer Medicine analysis of published studies.
May 9, 2019
0
4
Maintenance treatment with the PARP inhibitor rucaparib (Rubraca) was well tolerated and provided clinical responses among patients with advanced BRCA- or PALB2-mutated pancreatic cancer sensitive to platinum-based chemotherapy, ...
Apr 2, 2019
0
1
The vast majority of cancer deaths occur due to the spread of cancer from one organ to another, which can happen either through the blood or the lymphatic system. However, it can be tricky to detect this early enough. Researchers ...
Mar 14, 2019
0
1
Two University of Delaware researchers have developed a new approach to attack cancer, using two light-activated treatments that appear to be more effective together than when applied independently. More research is needed, ...
Mar 12, 2019
0
628
(HealthDay)—Long-term cardiomyopathy risk varies by chemotherapy agent for childhood cancer survivors, with a decreased risk for daunorubicin versus doxorubicin, according to a study recently published in JAMA Oncology.
Mar 1, 2019
0
2
